Finanzierungen und Anlageprodukte

Steuern

Homburger News

Share-Image Teamplate Deals-and-Cases

Homburger advised UBS in connection with PolyPeptide's EUR 151 m revolving credit facility agreement

On May 23, 2025, PolyPeptide announced that it has secured additional financing of EUR 40 m under its revolving credit facility (RCF) increasing the available capital commitments to a total of EUR 151 m, with UBS as coordinator and agent, and together with Danske Bank and Zürcher Kantonalbank each as mandated lead arranger and lender.
PolyPeptide is a global Contract Development &amp; Manufacturing Organization (CDMO) specializing in the development and manufacturing of peptide- and oligonucleotide-based active pharmaceutical ingredients for the biotech and pharmaceutical industries.
Homburger advised UBS and the other banks with regard to all Swiss legal aspects of the financing transaction. The Homburger team was led by Jürg Frick and included Nathalie Scherrer (both Financing and Investment Products) and Stefan Oesterhelt (Tax).

Homburger and UBS Switzerland, Migros Bank, Zürcher Kantonalbank

Homburger acted as counsel to UBS Switzerland AG as mandated lead arranger, coordinator, agent, security agent and original lender in connection with the refinancing of the Sequotech Group, an IT services group owned by multi-family office Verium AG and Sequotech’s management team.
Homburger advised UBS Switzerland AG, Migros Bank AG and Zürcher Kantonalbank with regard to all legal aspects of the financing transaction.
The Homburger team was led by Jürg Frick and included Nathalie Scherrer and Jannis Zafeirakos (all Financing and Investment Products) as well as Stefan Oesterhelt (Tax).

Homburger advised UBS Switzerland AG, Migros Bank AG and Zürcher Kantonalbank on the refinancing of the Sequotech Group

Deutsche Bank

Homburger advises Deutsche Bank AG, London Branch, on the financial restructuring of VARTA AG

Homburger acted as Swiss counsel to Deutsche Bank AG, London Branch, and the other syndicate banks, with regard to all Swiss legal aspects of the financing transaction for VARTA AG. VARTA AG produces and markets a diverse range of batteries including micro batteries, household batteries, energy storage systems and customer-battery solutions. As technology leader, VARTA AG sets industry standards in important areas of the battery technology field. VARTA AG is about to conclude complex financial restructuring proceedings initiated in July 2024 under the German StaRUG (German Act on the Stabilisation and Restructuring Framework for Companies). The restructuring plan was accepted in November 2024 and is to be finally implemented in the first quarter of 2025.
VARTA AG is to receive access to new credit facilities of EUR 60 m. The new facilities are a crucial part of the measures intended to secure VARTA AG&#8217;s core electronic battery industry, thereby helping to safe-guard jobs and value creation in Germany and Switzerland.
The Homburger team was led by Jürg Frick (Financing and Investment Products) and included Michelle Wolf and Nathalie Scherrer (both Financing and Investment Products) as well as Stefan Oesterhelt (Tax).

Nathalie
Scherrer

Homburger advised UBS in connection with PolyPeptide's EUR 151 m revolving credit facility agreement

Homburger advised UBS Switzerland AG, Migros Bank AG and Zürcher Kantonalbank on the refinancing of the Sequotech Group

Homburger advises Deutsche Bank AG, London Branch, on the financial restructuring of VARTA AG

Join the Team

Nathalie Scherrer

Karriere

Sprachen

Zulassung

Teams

NathalieScherrer

Homburger advised UBS in connection with PolyPeptide's EUR 151 m revolving credit facility agreement

Homburger advised UBS Switzerland AG, Migros Bank AG and Zürcher Kantonalbank on the refinancing of the Sequotech Group

Homburger advises Deutsche Bank AG, London Branch, on the financial restructuring of VARTA AG

Join the Team

Nathalie Scherrer

Karriere

Sprachen

Zulassung

Teams

Nathalie
Scherrer